Regeneron Pharmaceuticals REGN Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.12B+25.5% | $2.49B-9.1% | $2.74B-12.2% | $3.12B+7.6% | ||
| $5.49B-15.9% | $6.52B-19.6% | $8.11B+75.0% | $4.64B+65.0% | ||
| —— | —— | —— | —— | ||
| $5.74B-7.6% | $6.21B+9.6% | $5.67B+6.4% | $5.33B-11.7% | ||
| $3.2B+3.7% | $3.09B+19.6% | $2.58B+7.4% | $2.4B+23.1% | ||
| $641.5M-27.1% | $879.5M+11.4% | $789.3M-3.6% | $818.4M+13.4% | ||
| $1.64B+22.3% | $1.34B+19.7% | $1.12B+16.5% | $963.1M+36.2% | ||
| $474.8M+36.0% | $349.2M-9.7% | $386.6M-6.0% | $411.2M+23.7% | ||
| $18.02B-3.4% | $18.66B-4.2% | $19.48B+22.6% | $15.88B+13.3% | ||
| $40.56B+7.4% | $37.76B+14.1% | $33.08B+13.2% | $29.21B+14.9% | ||
| $939M+18.9% | $789.5M+30.2% | $606.6M+3.0% | $589.2M+4.5% | ||
| $553M-11.9% | $627.7M+36.8% | $458.9M-4.0% | $477.9M+8.1% | ||
| $37.8M+24.8% | $30.3M+59.5% | $19M+53.2% | $12.4M— | ||
| $0— | —— | —— | $0-100% | ||
| $4.37B+10.8% | $3.94B+15.2% | $3.42B+9.0% | $3.14B-20.1% | ||
| $1.99B+0.1% | $1.98B+0.1% | $1.98B+0.1% | $1.98B+0.1% | ||
| $720M0.0% | $720M0.0% | $720M0.0% | $720M0.0% | ||
| $266.8M+13.8% | $234.4M+167% | $87.7M— | —— | ||
| $720M0.0% | $720M0.0% | $720M0.0% | $720M— | ||
| $2.02B+28.5% | $1.57B+84.0% | $854.1M+33.9% | $638M-6.2% | ||
| $9.3B+10.7% | $8.41B+18.3% | $7.11B+8.5% | $6.55B-1.7% | ||
| $14B+8.9% | $12.86B+13.2% | $11.35B+14.1% | $9.95B+23.0% | ||
| $35.8B+13.0% | $31.67B+16.2% | $27.26B+17.0% | $23.31B+22.9% | ||
| $77.5M+1,081% | -$7.9M+90.2% | -$80.9M+66.1% | -$238.8M-811% | ||
| $18.61B+22.7% | $15.17B+20.8% | $12.56B+21.3% | $10.35B+25.3% | ||
| $31.26B+6.5% | $29.35B+13.0% | $25.97B+14.6% | $22.66B+20.8% | ||
| $40.56B+7.4% | $37.76B+14.1% | $33.08B+13.2% | $29.21B+14.9% | ||
| $190.2M+36.1% | $139.8M-5.1% | $147.3M+49.4% | $98.6M+33.8% | ||
| $5.49B-15.9% | $6.52B-19.6% | $8.11B+75.0% | $4.64B+65.0% | ||
| $727.5M+0.2% | $725.7M+39.0% | $522.1M-27.6% | $720.7M+41.3% | ||
| $334M+109% | $159.8M+115% | $74.3M+53.8% | $48.3M+20.8% | ||
| $1.82B+60.3% | $1.14B+156% | $444.1M+32.0% | $336.4M+55.7% | ||
| $34.3M— | —— | —— | —— | ||
| $334M+109% | $159.8M+115% | $74.3M+53.8% | $48.3M+20.8% | ||
| $34.3M— | —— | —— | —— | ||
| $334M+109% | $159.8M+115% | $74.3M+53.8% | $48.3M+20.8% | ||
| $4.08B+23.0% | $3.31B+28.7% | $2.58B+49.4% | $1.72B+96.6% | ||
| $1.26B+9.5% | $1.15B+10.6% | $1.04B+13.4% | $915.5M+13,564% | ||
| $10.26B+15.3% | $8.9B+64.9% | $5.4B-18.1% | $6.59B-3.6% | ||
| $1.82B+60.3% | $1.14B+156% | $444.1M+32.0% | $336.4M+55.7% | ||
| $5.12B+11.3% | $4.6B+10.9% | $4.15B+10.2% | $3.76B+8.1% | ||
| $1.82B+60.3% | $1.14B+156% | $444.1M+32.0% | $336.4M+55.7% | ||
| $208.7M+12.4% | $185.7M+46.6% | $126.7M+81.5% | $69.8M-4.8% | ||
| $208.7M+12.4% | $185.7M+46.6% | $126.7M+81.5% | $69.8M-4.8% | ||
| $2.88B+13.8% | $2.53B+7.2% | $2.36B+13.7% | $2.07B-6.0% | ||
| $208.7M+12.4% | $185.7M+46.6% | $126.7M+81.5% | $69.8M-4.8% | ||
| $2.97B+1.2% | $2.94B+5.3% | $2.79B+2.8% | $2.71B+0.5% | ||
| $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | ||
| $15.62B+8.9% | $14.34B+13.5% | $12.64B+22.4% | $10.32B+22.4% | ||
| $2.5M-93.6% | $39M-66.3% | $115.8M-61.8% | $302.8M+616% | ||
| $98.5M+227% | $30.1M+120% | $13.7M+1,422% | $900K-91.7% | ||
| $15.62B+8.9% | $14.34B+13.5% | $12.64B+22.4% | $10.32B+22.4% | ||
| $10.22B+31.0% | $7.8B+76.8% | $4.41B-18.0% | $5.38B-3.7% | ||
| $5.49B-15.9% | $6.52B-19.6% | $8.11B+75.0% | $4.64B+65.0% | ||
| $15.71B+9.7% | $14.33B+14.3% | $12.53B+25.1% | $10.02B+19.3% | ||
| $1.5M— | $0-100% | $4.6M+1,050% | $400K— | ||
| $334M+109% | $159.8M+115% | $74.3M+53.8% | $48.3M+20.8% | ||
| $0— | —— | —— | $0-100% | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| 30M0.0% | 30M0.0% | 30M0.0% | 30M0.0% | ||
| 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | ||
| —— | —— | —— | —— | ||
| 33.7M+19.5% | 28.2M+10.6% | 25.5M+12.8% | 22.6M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regeneron Pharmaceuticals's total assets?
- Regeneron Pharmaceuticals (REGN) holds $40.9B in total assets, up 8.8% year over year.
- How much debt does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals carries $2.7B in total debt against $31.4B of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals holds $3.0B in cash and equivalents.
- Can Regeneron Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.56 — current assets exceed current liabilities.
- Where does Regeneron Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
